SC
ABBV icon

Samlyn Capital’s AbbVie ABBV Stock Holding History

Samlyn Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-347,025
Closed -$34.1M – 139
2020
Q2 		$34.1M Sell
347,025
-253,498
-42% -$22.3M 0.63% 51
2020
Q1 		$45.8M Buy
+600,523
New +$51.2M 1.15% 36
2015
Q4 		– Sell
-244,000
Closed -$13.3M – 78
2015
Q3 		$13.3M Buy
+244,000
New +$15.9M 0.24% 77
2014
Q4 		– Sell
-2,194,297
Closed -$127M – 100
2014
Q3 		$127M Sell
2,194,297
-62,500
-3% -$3.47M 2.62% 4
2014
Q2 		$127M Sell
2,256,797
-108,887
-5% -$5.71M 2.89% 5
2014
Q1 		$122M Buy
2,365,684
+1,029,431
+77% +$52M 2.83% 4
2013
Q4 		$70.6M Sell
1,336,253
-652,217
-33% -$32.1M 1.77% 21
2013
Q3 		$88.9M Buy
1,988,470
+104,370
+6% +$4.63M 2.48% 6
2013
Q2 		$77.9M Buy
+1,884,100
New +$82.4M 2.27% 7

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Samlyn Capital's ABBV Position: Q3 2020 in Review

Samlyn Capital sold out of AbbVie (ABBV) in Q3 2020, closing a stake of 347,025 shares — an estimated $34.1M sold.

Samlyn Capital first reported a position in ABBV in Q2 2013 and held it in 9 quarters. The position peaked at $127M in Q2 2014. 2,366 funds tracked by Wall St. Rank hold ABBV as of Q3 2020.

  • Samlyn Capital reported no remaining AbbVie position as of Q3 2020 after selling out during the quarter.
  • Samlyn Capital sold 347,025 AbbVie shares in Q3 2020, an estimated $34.1M.
  • Samlyn Capital first reported a position in AbbVie in Q2 2013 and held it in 9 quarters.
  • Samlyn Capital's AbbVie position peaked at $127M in Q2 2014.
  • 2,366 funds tracked by Wall St. Rank held AbbVie as of Q3 2020.

Based on Samlyn Capital's 13F filing for Q3 2020, filed 16 Nov 2020.